PT-141 (Bremelanotide)

What Is PT-141?

PT-141 (Bremelanotide) is a synthetic peptide derived from Melanotan-2 that acts as a melanocortin receptor agonist, primarily targeting the MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors that work on vascular mechanisms, PT-141 acts directly on the brain’s arousal pathways to influence sexual desire and response.

Originally developed during Melanotan-2 research when subjects reported significant increases in sexual arousal, PT-141 was isolated and refined specifically for its effects on sexual function. It received FDA approval in 2019 as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first melanocortin-based therapeutic approved for sexual dysfunction.

Mechanism of Action

Central Nervous System Activation

PT-141 crosses the blood-brain barrier and binds to melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system. This activation triggers downstream signaling cascades that modulate dopaminergic and oxytocinergic pathways involved in sexual arousal and desire.

Dopamine Pathway Modulation

MC4R activation by PT-141 increases dopamine release in the medial preoptic area (MPOA) and nucleus accumbens, brain regions directly associated with sexual motivation and reward. This mechanism explains why PT-141 influences desire itself rather than just physiological response.

Oxytocin Release

Research indicates PT-141 stimulates oxytocin release from the paraventricular nucleus of the hypothalamus. Oxytocin plays a role in sexual arousal, bonding, and the physiological reflexes associated with sexual response in both sexes.

Gender-Independent Activity

Because PT-141 works through central melanocortin pathways rather than peripheral vascular mechanisms, it demonstrates efficacy in both male and female research subjects – a distinction from vascular-targeted compounds that primarily benefit male subjects.

Research Applications

• Female sexual dysfunction – HSDD and generalized arousal disorder models
• Male erectile dysfunction – Particularly in subjects non-responsive to PDE5 inhibitors
• Central arousal mechanisms – Studying melanocortin receptor roles in sexual motivation
• Dopaminergic pathway research – Investigating MC4R-mediated dopamine release in reward circuits
• Oxytocin signaling – Exploring melanocortin-oxytocin crosstalk in social and sexual behavior
• Combination protocols – Paired with hormonal optimization in comprehensive sexual health research

Dosing Protocols

All protocols are for research reference only. Consult a qualified medical professional before use.

Preparation & Storage

Reconstitution

Supplies: peptide vial, bacteriostatic water, insulin syringes (29–31 gauge), alcohol swabs.

1. Clean both vial tops with alcohol swabs and let dry
2. Draw 2 mL of bacteriostatic water into the syringe
3. Insert needle into peptide vial at an angle against the glass wall
4. Let water run slowly down the side – never squirt directly onto powder
5. Gently swirl until fully dissolved – never shake
6. Solution should be clear – discard if cloudy or contains particles

Concentration: 10 mg in 2 mL = 5,000 mcg/mL

Storage

• Unreconstituted: Room temp or refrigerated, stable up to 24 months
• Reconstituted: Refrigerate at 2–8°C (36–46°F), use within 4–6 weeks
• Protect from direct sunlight and heat
• Do not freeze reconstituted solution

Cycling

Typical research cycle: As needed. Results generally reported within 30–60 min.